ALVO

BofA Securities initiated coverage of Alvotech with a rating of Buy and set a new price target of $7.00

6-K - Alvotech (0001898416) (Filer)

REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed biosimilar to Hemlibra® (emicizumab). Imfinzi® is an oncology biologic used in the treatment of multiple cancers, which generated global sales of approximately $6.1 billion in 2025¹. Hemlibra® is a

6-K - Alvotech (0001898416) (Filer)

REYKJAVIK, Iceland, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the first half of 2026 and provided a business update. A supplemental long‑form earnings release and management presentation providing additional details and business update is available on our website: https://alvotech.com/financials.1 H1 2026 financial highlights Adjusted total revenue2 was $211.9 million compared to $306.1 million in the same period last year.Gross Margin of 54% was broadly level wi

Evercore ISI initiated coverage of Alvotech with a rating of Outperform

REYKJAVIK, Iceland, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close. The Company will also host a webcast with a live Q&A on Thursday, August 20, 2026, at 08:00 ET (12:00 GMT, 13:00 BST, 14:00 CEST). To listen to the webcast, please register here: H1 2026 webcastTo participate in the Q&A, please register here: Q&A registration Slides and other material will be made available on alvot

6-K - Alvotech (0001898416) (Filer)

REYKJAVIK, Iceland, July 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has closed its inspection of the company’s manufacturing facility in Reykjavik, Iceland, conducted in May 2026. The FDA has confirmed the inspection classification of the manufacturing site is Voluntary Action Indicated (VAI). "This is an important milestone for Alvotech and reflects the significant work our teams have undertaken to further strengthen our quality systems and manufacturing operatio

6-K - Alvotech (0001898416) (Filer)

— $75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management — Follows recent $165m equity raise strengthening cash position — Including equity financing and undrawn loan facility, Alvotech has secured access to $240 million in new capital — Funds will support execution across Alvotech’s R&D pipeline and global product launches REYKJAVIK, Iceland, July 01, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has amended its existing credit agreement with funds managed by GoldenTree Ass

6-K - Alvotech (0001898416) (Filer)

REYKJAVIK, Iceland, June 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the "Offering") of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deductin

6-K - Alvotech (0001898416) (Filer)

424B5 - Alvotech (0001898416) (Filer)

FWP - Alvotech (0001898416) (Subject)

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the "Offering") of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up

FWP - Alvotech (0001898416) (Subject)

424B5 - Alvotech (0001898416) (Filer)

6-K - Alvotech (0001898416) (Filer)

REYKJAVIK, Iceland, June 15, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has commenced an underwritten public offering of its ordinary shares (the "Offering"). In addition, Alvotech expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares sold in the public offering at the public offering price, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when

6-K - Alvotech (0001898416) (Filer)

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration. Under a partnership with Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), Alvotech is responsible for development and manufacturing of AVT16, while Teva is responsible for commercialization. "FDA acceptance of the BLA f

6-K - Alvotech (0001898416) (Filer)

REYKJAVIK, Iceland, June 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the resubmission to the U.S. Food and Drug Administration (FDA) of Biologics License Applications (BLAs) for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab), and AVT06, a proposed biosimilar to Eylea® (aflibercept) 2 mg. Under a partnership with Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), Alvotech is responsible for the development and manufacturing of AVT05 and AVT06, while Teva is responsible for commercialization. The r